Holen Sie sich die Stockscreener-App
13.45
3.70%
0.48
Handel nachbörslich:
13.60
0.15
+1.12%
Schlusskurs vom Vortag:
$12.97
Offen:
$13.17
24-Stunden-Volumen:
2.34M
Relative Volume:
1.04
Marktkapitalisierung:
$1.16B
Einnahmen:
$139.71M
Nettoeinkommen (Verlust:
$-209.36M
KGV:
-4.5439
EPS:
-2.96
Netto-Cashflow:
$-160.60M
1W Leistung:
+4.34%
1M Leistung:
+40.25%
6M Leistung:
-10.81%
1J Leistung:
-32.31%
1-Tages-Spanne:
$13.02
$13.60
1-Wochen-Bereich:
$12.10
$13.60
52-Wochen-Spanne:
$8.58
$22.50
Syndax Pharmaceuticals Inc Stock (SNDX) Company Profile
Firmenname
Syndax Pharmaceuticals Inc
Sektor
Branche
Telefon
781-419-1400
Adresse
730 THIRD AVENUE, NEW YORK, MA
Vergleichen Sie SNDX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SNDX
Syndax Pharmaceuticals Inc
|
13.45 | 1.12B | 139.71M | -209.36M | -160.60M | -2.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Syndax Pharmaceuticals Inc Stock (SNDX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-05 | Bestätigt | BTIG Research | Buy |
| 2025-07-10 | Eingeleitet | Goldman | Buy |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-06-28 | Eingeleitet | Jefferies | Buy |
| 2024-01-31 | Herabstufung | Scotiabank | Sector Outperform → Sector Perform |
| 2023-12-22 | Eingeleitet | Mizuho | Buy |
| 2023-10-25 | Eingeleitet | BofA Securities | Buy |
| 2023-10-11 | Eingeleitet | Goldman | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Outperform |
| 2023-07-11 | Eingeleitet | Guggenheim | Buy |
| 2023-04-17 | Fortgesetzt | BTIG Research | Buy |
| 2023-01-31 | Eingeleitet | Stifel | Buy |
| 2023-01-03 | Eingeleitet | JP Morgan | Overweight |
| 2022-07-28 | Fortgesetzt | B. Riley Securities | Buy |
| 2022-04-11 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-02-15 | Eingeleitet | Goldman | Buy |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Outperform |
| 2021-05-25 | Eingeleitet | Citigroup | Buy |
| 2021-02-18 | Eingeleitet | B. Riley Securities | Buy |
| 2020-12-03 | Eingeleitet | Stifel | Buy |
| 2020-05-22 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-05-22 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2020-05-18 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-05-11 | Bestätigt | H.C. Wainwright | Buy |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-01-13 | Bestätigt | H.C. Wainwright | Buy |
| 2019-03-08 | Bestätigt | H.C. Wainwright | Buy |
| 2019-01-04 | Eingeleitet | Robert W. Baird | Outperform |
| 2018-01-05 | Eingeleitet | B. Riley FBR, Inc. | Buy |
| 2017-03-16 | Eingeleitet | FBR & Co. | Outperform |
| 2017-03-02 | Eingeleitet | Instinet | Buy |
| 2016-10-07 | Eingeleitet | Guggenheim | Buy |
| 2016-03-28 | Eingeleitet | Citigroup | Buy |
| 2016-03-28 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2016-03-28 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Syndax Pharmaceuticals Inc Aktie (SNDX) Neueste Nachrichten
Syndax Pharmaceuticals: A Tale of Two Drug Launches - AInvest
Syndax Pharmaceuticals: A Tale Of Two Drug Launches (NASDAQ:SNDX) - Seeking Alpha
Syndax Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:SNDX) - MarketBeat
FDA Priority Review and Revenue Growth Drive Short-Term Upswing for Syndax Pharmaceuticals - Insider Monkey
Syndax Pharmaceuticals' Path to Blockbuster Status: Leveraging FDA Priority Review and Revenue Growth in Oncology - AInvest
S&E In Brief: Launch Updates And Political Headwinds - insights.citeline.com
What makes Syndax Pharmaceuticals Inc. stock price move sharplyLow Cost High Gain Picks - mustnews.co.kr
Syndax Pharmaceuticals (NASDAQ:SNDX) Upgraded by B. Riley to Strong-Buy Rating - MarketBeat
Syndax jumps after Q2 beat; Citi issues upside catalyst watch - MSN
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Analysts Just Made A Massive Upgrade To Their Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Forecasts - 富途牛牛
Analysts Boost Syndax Pharmaceuticals' Forecasts, Revenue and EPS Estimates Increase - AInvest
Analysts Just Made A Dazzling Upgrade To Their Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Forecasts - au.finance.yahoo.com
11 Best Short-Term Stocks to Invest in - Insider Monkey
Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Gap Up on Better-Than-Expected Earnings - MarketBeat
Syndax Pharmaceuticals Publishes Positive Revumenib Data from BEAT AML Trial - MSN
Q3 Earnings Forecast for SNDX Issued By B. Riley - MarketBeat
Citigroup Increases Syndax Pharmaceuticals (NASDAQ:SNDX) Price Target to $51.00 - MarketBeat
BTIG Research Forecasts Strong Price Appreciation for Syndax Pharmaceuticals (NASDAQ:SNDX) Stock - MarketBeat
Syndax Pharmaceuticals (NASDAQ:SNDX) Issues Quarterly Earnings Results, Beats Estimates By $0.18 EPS - MarketBeat
Citi Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Announces Target Price $51 - 富途牛牛
Citi Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Maintains Target Price $51 - 富途牛牛
XTX Topco Ltd Invests $783,000 in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Syndax targets expanded $10B market opportunity with Revuforj and Niktimvo amid accelerating adoption and guidance for stable expenses - MSN
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
Syndax Pharmaceuticals Announces Inducement Stock Grants Under NASDAQ Listing Rule 5635(c)(4) - AInvest
Citi Raises Syndax Target to $51, Adds Positive Catalyst Watch - AInvest
Citi ups Syndax target, opens ‘upside catalyst watch’ - Yahoo Finance
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q2 2025 Earnings Call Transcript - Insider Monkey
Three Stocks to Buy Now: Harmony Biosciences, Syndax Pharmaceuticals, and Viper Energy - AInvest
Optimistic Investors Push Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Up 40% But Growth Is Lacking - simplywall.st
Syndax Pharmaceuticals Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Syndax Pharmaceuticals Faces Ongoing and Emerging Business Risks: A Closer Look at SEC Filings - TipRanks
Decoding Syndax Pharmaceuticals Inc (SNDX): A Strategic SWOT Ins - GuruFocus
Citigroup Raises SNDX Price Target Amid "Buy" Rating - AInvest
Syndax Pharmaceuticals’ Earnings Call Highlights Robust Growth - TipRanks
Syndax Pharmaceuticals (SNDX) Reports Q2 Loss, Beats Revenue Estimates - MSN
Evaluating the High-Growth Potential of Biopharma Innovators in 2025: A Deep Dive into Day One, Beam Therapeutics, and Syndax Pharmaceuticals - AInvest
Syndax Pharmaceuticals Shares Rise After Q2 Results Beat - MarketScreener
Citigroup Raises Syndax PT to $51 from $46, Maintains Buy Rating - AInvest
Syndax Pharmaceuticals (SNDX) Surges on Strong Q2 2025 Results - GuruFocus
BTIG Raises Price Target for SNDX, Maintains Buy Rating | SNDX S - GuruFocus
Syndax Pharmaceuticals Q2 Earnings Exceed Expectations, Citi Issues Upside Catalyst Watch - AInvest
Syndax stock up as Citi issues catalyst watch (SNDX:NASDAQ) - Seeking Alpha
Syndax Stock (SNDX) Moves Higher: Analysts Raise PTs on Strong Revenue, Approaching Catalyst - AskTraders.com
Syndax Pharmaceuticals: The Story Brightens (NASDAQ:SNDX) - Seeking Alpha
Syndax Pharmaceuticals shares surge 17.44% intraday after Q2 earnings beat expectations, driven by strong revenue from Revuforj and Niktimvo. - AInvest
Syndax stock price target raised to $20 from $18 at Goldman Sachs - Investing.com Canada
Health Check: How Prudently Does Syndax Pharmaceuticals (NASDAQ:SNDX) Use Debt? - simplywall.st
Syndax Pharmaceuticals Shares Soar 12.62% on Strong Q2 Earnings - AInvest
Syndax: Q2 Earnings Snapshot - New Haven Register
Finanzdaten der Syndax Pharmaceuticals Inc-Aktie (SNDX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):